UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock. Several other equities research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued […]
D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report published on Wednesday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock. Several other equities research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued […]
